The EGFR-MET targeting bispecific antibody amivantamab has also been shown to induce more robust ADCC than cetuximab, and a direct correlation was established between the ADCC activity and secreted interferon γ levels in preclinical NSCLC models with EGFR exon 20 insertions (163). The gene discussed is MET; the disease is non-small cell lung carcinoma.